Search

Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final Psoriasis Area Severity Index (PASI) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis. [ABSTRACT FROM AUTHOR]

The article offers information on the case of a 57-year-old man who was presented because of asymptomatic glans penis lesion. It states that the man was diagnosed with stage IV prostatic adenocarcinoma with presence of pelvic metastases. It mentions that diagnosis of penile metastases was made after the immunohistochemical study shows prostatic-specific antigen in dermal cellular.

Background Management of facial extensive recurrent basal cell carcinoma can be a challenge for dermatologists. Although the preferred technique is usually Mohs surgery, sometimes the patient's condition or predicted aggressive surgery make other options advisable. Methods We describe a case of a giant recurrent basal cell carcinoma in the face of an old woman successfully treated by combined therapy with MAL-photodynamic therapy and topical 5%. Results The patient remains well and with no sign of the tumor, with very good cosmetic result two years after treatment. Conclusions Management of extensive facial basal cell carcinoma with combined therapies, as photodynamic therapy followed by topical imiquimod, can be an option for selected cases such as ours. [ABSTRACT FROM AUTHOR]

A letter to the editor is presented discussing the case of a 34-year-old man with plaque-type blue nevus on the palm.

A letter to the editor is presented concerning a case study of a 54-year-old woman who was admitted to the hospital with a painful and cramping plaque involving her left hemiface.

A letter to the editor is presented which discusses two medical cases of Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) caused by omeprazole.

Clustered or agminated juvenile xanthogranuloma (JXG) is an unusual form of JXG characterized by multiple reddish-brown or yellowish papules and nodules in a coalescent pattern. We report a case of clustered JXG involving the left lower back of a 5-month-old boy. [ABSTRACT FROM AUTHOR]

The article presents a case study of a 68-year-old woman who was presented with a nine-year history of a relapsing cutaneous eruption on the body. It says that the patient was diagnosed with erythema elevatum diutinum (EED) based on the clinical appearance and histology, in which dapsone was used for the treatment. Furthermore, it mentions that EED is a rare skin disease and a low-grade form of leukocytoclastic vasculitis, in which etiology is unknown.